Jushi Issue Statement On Pennsylvania Commonwealth Court Vape Ruling

Here it is

Jushi Holdings Inc. Issues Statement on Commonwealth Court of Pennsylvania Order Lifting the Stay of Temporary Injunctive Relief in Case Challenging Vaporization Product Recall 

 

BOCA RATON, Fla., June 16, 2022 — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, issued the following statement on the Commonwealth Court of Pennsylvania granting Medical Marijuana Access & Patient Safety, Inc.’s (“MMAPS”) application to vacate the automatic stay of injunctive relief ordered on June 2, 2022, temporarily halting the Pennsylvania Department of Health’s (“DOH” or the “Department”) recall of certain vaporized medical marijuana products.

______________________________________________________________

On behalf of Pennsylvania’s medical marijuana patient community, we would like to extend our appreciation to the Commonwealth Court for its thoughtful assessment of the facts and circumstances upon which DOH’s February recall of tested, approved medical marijuana vaporization products containing terpenes was based, and for the subsequent orders issued on June 2 and June 15 allowing responsible operators to again make these products accessible to patients.

In light of the Court’s Orders, impacted products will be back on the shelves of BEYOND/HELLOTM dispensaries today and the shelves of our partner dispensaries across the Commonwealth in the coming days.

After receiving documents and testimony offered by MMAPS, the Court came to the unambiguous conclusion that DOH “failed to present any evidence” of potential harm to medical marijuana patients associated with the recalled products,” noting that the Department did not call any witnesses or present any evidence of patient complaints or adverse events during the preliminary injunction hearing.

Under Pennsylvania law, all medical marijuana products, including the recalled vaporization products, are subject to rigorous, redundant safety and quality testing and Department approval before they can be manufactured or dispensed. As to the recalled products specifically, DOH was neither able to cite a safety or quality testing deficiency nor a single adverse event relating to any recalled products.

“The Court’s June 2 and June 15 Orders are about more than just preserving patient access to tested, approved, and for many patients, effective medical marijuana products – they deliver peace of mind to thousands of Pennsylvanians that health risks cited by the Department could not be substantiated in any way or any extent.  In fact, the Court noted the Department itself approved the recalled products for patient use following stringent quality and safety testing and found no evidence of a single adverse event related to any recalled product.”  said Jim Cacioppo, Chief Executive Officer, Chairman, and Founder for Jushi Holdings Inc.

Nothing is more important to Jushi than the health and wellbeing of our customers, especially medical cannabis patients. We will continue to make best in class products available to Pennsylvanians suffering from serious medical conditions and support MMAPS’ effort to ensure patients have access to tested, regulated products best suited to relieve their symptoms.

Today is a win for medical marijuana patients, their families, and caregivers across the Commonwealth.

Primary Sponsor

New: Free USA Cannabis Case Law Search – New Cases Daily

Top Marijuana Blog